Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial von Gettinger, Scott N, Dr, Bazhenova, Lyudmila A, Prof, Langer, Corey J, Prof, Salgia, Ravi, Prof, Gold, Kathryn A, MD, Rosell, Rafael, Prof, Shaw, Alice T, MD, Weiss, Glen J, MD, Tugnait, Meera, PhD, Narasimhan, Narayana I, PhD, Dorer, David J, PhD, Kerstein, David, MD, Rivera, Victor M, PhD, Clackson, Timothy, PhD, Haluska, Frank G, MD, Camidge, David Ross, Prof

Volltext

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial von Camidge, D. Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C. H., Han, Ji-Youn, Hochmair, Maximilian J., Lee, Ki Hyeong, Delmonte, Angelo, Garcia Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander, Gettinger, Scott N., Tiseo, Marcello, Lin, Huamao M., Gupta, Neeraj, Hanley, Michael J., Ni, Quanhong, Zhang, Pingkuan, Popat, Sanjay

Volltext

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study von Hellmann, Matthew D, Dr, Rizvi, Naiyer A, Prof, Goldman, Jonathan W, MD, Gettinger, Scott N, MD, Borghaei, Hossein, DO, Brahmer, Julie R, MD, Ready, Neal E, Prof, Gerber, David E, MD, Chow, Laura Q, MD, Juergens, Rosalyn A, MD, Shepherd, Frances A, Prof, Laurie, Scott A, MD, Geese, William J, PhD, Agrawal, Shruti, PhD, Young, Tina C, MS, Li, Xuemei, MD, Antonia, Scott J, Prof

Volltext

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients von Herbst, Roy S., Soria, Jean-Charles, Kowanetz, Marcin, Fine, Gregg D., Hamid, Omid, Gordon, Michael S., Sosman, Jeffery A., McDermott, David F., Powderly, John D., Gettinger, Scott N., Kohrt, Holbrook E. K., Horn, Leora, Lawrence, Donald P., Rost, Sandra, Leabman, Maya, Xiao, Yuanyuan, Mokatrin, Ahmad, Koeppen, Hartmut, Hegde, Priti S., Mellman, Ira, Chen, Daniel S., Hodi, F. Stephen

Volltext

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial von Goldberg, Sarah B, Dr, Gettinger, Scott N, MD, Mahajan, Amit, MD, Chiang, Anne C, MD, Herbst, Roy S, Prof, Sznol, Mario, Prof, Tsiouris, Apostolos John, MD, Cohen, Justine, DO, Vortmeyer, Alexander, MD, Jilaveanu, Lucia, MD, Yu, James, MD, Hegde, Upendra, MD, Speaker, Stephanie, BA, Madura, Matthew, BS, Ralabate, Amanda, BSN, Rivera, Angel, MS, Rowen, Elin, MSN, Gerrish, Heather, BSN, Yao, Xiaopan, PhD, Chiang, Veronica, MD, Kluger, Harriet M, Prof

Volltext

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial von Camidge, D. Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C.H., Han, Ji-Youn, Hochmair, Maximilian J., Lee, Ki Hyeong, Delmonte, Angelo, Garcia Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander I., Gettinger, Scott N., Tiseo, Marcello, Lin, Huamao M., Liu, Yuyin, Vranceanu, Florin, Niu, Huifeng, Zhang, Pingkuan, Popat, Sanjay

Volltext

Oncolytic virus immunotherapy: future prospects for oncology von Raja, Junaid, Ludwig, Johannes M, Gettinger, Scott N, Schalper, Kurt A, Kim, Hyun S

Volltext

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA von Goldberg, Sarah B, Narayan, Azeet, Kole, Adam J, Decker, Roy H, Teysir, Jimmitti, Carriero, Nicholas J, Lee, Angela, Nemati, Roxanne, Nath, Sameer K, Mane, Shrikant M, Deng, Yanhong, Sukumar, Nitin, Zelterman, Daniel, Boffa, Daniel J, Politi, Katerina, Gettinger, Scott N, Wilson, Lynn D, Herbst, Roy S, Patel, Abhijit A

Volltext

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis von Magnuson, William J, Lester-Coll, Nataniel H, Wu, Abraham J, Yang, T Jonathan, Lockney, Natalie A, Gerber, Naamit K, Beal, Kathryn, Amini, Arya, Patil, Tejas, Kavanagh, Brian D, Camidge, D Ross, Braunstein, Steven E, Boreta, Lauren C, Balasubramanian, Suresh K, Ahluwalia, Manmeet S, Rana, Niteshkumar G, Attia, Albert, Gettinger, Scott N, Contessa, Joseph N, Yu, James B, Chiang, Veronica L

Volltext

Immuno-thermal ablations - boosting the anticancer immune response von Slovak, Ryan, Ludwig, Johannes M, Gettinger, Scott N, Herbst, Roy S, Kim, Hyun S

Volltext

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial von Huber, Rudolf M., Hansen, Karin H., Paz-Ares Rodríguez, Luis, West, Howard L., Reckamp, Karen L., Leighl, Natasha B., Tiseo, Marcello, Smit, Egbert F., Kim, Dong-Wan, Gettinger, Scott N., Hochmair, Maximilian J., Kim, Sang-We, Langer, Corey J., Ahn, Myung-Ju, Kim, Edward S., Kerstein, David, Groen, Harry J.M., Camidge, D. Ross

Volltext

Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo von Foggetti, Giorgia, Li, Chuan, Cai, Hongchen, Hellyer, Jessica A., Lin, Wen-Yang, Ayeni, Deborah, Hastings, Katherine, Choi, Jungmin, Wurtz, Anna, Andrejka, Laura, Maghini, Dylan G., Rashleigh, Nicholas, Levy, Stellar, Homer, Robert, Gettinger, Scott N., Diehn, Maximilian, Wakelee, Heather A., Petrov, Dmitri A., Winslow, Monte M., Politi, Katerina

Volltext

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403 von Goldberg, Sarah B., Redman, Mary W., Lilenbaum, Rogerio, Politi, Katerina, Stinchcombe, Thomas E., Horn, Leora, Chen, Everett H., Mashru, Sandeep H., Gettinger, Scott N., Melnick, Mary Ann, Herbst, Roy S., Baumgart, Megan A., Miao, Jieling, Moon, James, Kelly, Karen, Gandara, David R.

Volltext

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC) von Carvajal-Hausdorf, Daniel, Altan, Mehmet, Velcheti, Vamsidhar, Gettinger, Scott N, Herbst, Roy S, Rimm, David L, Schalper, Kurt A

Volltext

Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases von Magnuson, William J., MD, Yeung, Jacky T., MD, Guillod, Paul D., BS, Gettinger, Scott N., MD, Yu, James B., MD, Chiang, Veronica L., MD

Volltext

Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep Sequencing von NARAYAN, Azeet, CARRIERO, Nicholas J, GETTINGER, Scott N, KLUYTENAAR, Jeannie, KOZAK, Kevin R, YOCK, Torunn I, MUSCATO, Nicole E, UGARELLI, Pedro, DECKER, Roy H, PATEL, Abhijit A

Volltext

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study von Horn, Leora, Gettinger, Scott N., Gordon, Michael S., Herbst, Roy S., Gandhi, Leena, Felip, Enriqueta, Sequist, Lecia V., Spigel, David R., Antonia, Scott J., Balmanoukian, Ani, Cassier, Philippe A., Liu, Bo, Kowanetz, Marcin, O'Hear, Carol, Fassò, Marcella, Grossman, William, Sandler, Alan, Soria, Jean-Charles

Volltext

A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non―Small Cell Lung Cancer von JOHUNG, Kimberly L, XIAOPAN YAO, FANGYONG LI, YU, James B, GETTINGER, Scott N, GOLDBERG, Sarah, DECKER, Roy H, HESS, Judith A, CHIANG, Veronica L, CONTESSA, Joseph N

Volltext

Programmed death ligand-1 expression in non-small cell lung cancer von Velcheti, Vamsidhar, Schalper, Kurt A, Carvajal, Daniel E, Anagnostou, Valsamo K, Syrigos, Konstantinos N, Sznol, Mario, Herbst, Roy S, Gettinger, Scott N, Chen, Lieping, Rimm, David L

Volltext

Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non–Small-Cell Lung Cancer: Results of a Phase I/II Trial von SOCINSKI, Mark A, STINCHCOMBE, Thomas E, MORRIS, David E, MOORE, Dominic T, GETTINGER, Scott N, DECKER, Roy H, PETTY, W. Jeffrey, BLACKSTOCK, A. William, SCHWARTZ, Garry, LANKFORD, Scott, KHANDANI, Amir

Volltext